Clinical Trial Update: Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap [Phase 2]

View source ↗

Summary

Bayer's Bay1002670 Phase 2 trial for uterine fibroids has completed with posted safety and efficacy results across the EU, United States, Canada, and Japan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• BAY1002670

Snippet

Sponsor: Bayer | Conditions: Leiomyoma | Phase 2 | Status: COMPLETED | Results posted: 2017-12-08